These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 19713984)

  • 1. Hepatitis C: The role of new interferons in the era of STAT-C.
    Moucari R; Marcellin P
    Nat Rev Gastroenterol Hepatol; 2009 Sep; 6(9):509-11. PubMed ID: 19713984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin.
    Diago M; Hassanein T; Rodés J; Ackrill AM; Sedarati F
    Ann Intern Med; 2004 Jan; 140(1):72-3. PubMed ID: 14706990
    [No Abstract]   [Full Text] [Related]  

  • 3. Hepatitis C: CIFN for re-treatment of PEG-IFN plus RBV nonresponders?
    Trepo C; Pradat P
    Nat Rev Gastroenterol Hepatol; 2009 Oct; 6(10):570-1. PubMed ID: 19789573
    [No Abstract]   [Full Text] [Related]  

  • 4. Boceprevir and peginterferon α-2b plus ribavirin therapy of HCV genotype 3 relapsers: A pilot study.
    Lee SS; Kilvert L; Liu H; Trepanier J
    Dig Liver Dis; 2016 Mar; 48(3):344. PubMed ID: 26459137
    [No Abstract]   [Full Text] [Related]  

  • 5. Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.
    Lukasiewicz E; Hellstrand K; Westin J; Ferrari C; Neumann AU; Pawlotsky JM; Schalm SW; Zeuzem S; Veldt BJ; Hansen BE; Verhey-Hart E; Lagging M
    Hepatology; 2007 Jan; 45(1):258-9. PubMed ID: 17187414
    [No Abstract]   [Full Text] [Related]  

  • 6. Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.
    Yu ML; Dai CY; Huang JF; Chuang WL
    Hepatology; 2008 Sep; 48(3):1019-20; author reply 1020-1. PubMed ID: 18756469
    [No Abstract]   [Full Text] [Related]  

  • 7. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
    Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHESYS study.
    D'heygere F; George C; Habersetzer F; Tripathi D; Q Pan C; Giron JA; Schmitz M; Tatsch F
    Ann Hepatol; 2014; 13(2):303-4. PubMed ID: 24558225
    [No Abstract]   [Full Text] [Related]  

  • 9. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.
    Di Bisceglie AM; Ghalib RH; Hamzeh FM; Rustgi VK
    J Viral Hepat; 2007 Oct; 14(10):721-9. PubMed ID: 17875007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment with novel triple drug combination consisting of interferon-gamma, interferon alfacon-1, and ribavirin in a nonresponder HCV patient to pegylated interferon therapy.
    Balan V; Rosati MJ; Anderson MH; Rakela J
    Dig Dis Sci; 2006 May; 51(5):956-9. PubMed ID: 16758306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
    Liu CJ; Chuang WL; Lee CM; Yu ML; Lu SN; Wu SS; Liao LY; Chen CL; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Liu CH; Su WW; Lin CL; Jeng YM; Chen PJ; Chen DS
    Gastroenterology; 2009 Feb; 136(2):496-504.e3. PubMed ID: 19084016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection.
    Feld JJ
    Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):429-44. PubMed ID: 23199502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Is 24 weeks of peginterferon and ribavirin combination therapy sufficient for the patients with genotype 1 chronic hepatitis C?].
    Song BC
    Korean J Gastroenterol; 2010 Jul; 56(1):59-61. PubMed ID: 20664319
    [No Abstract]   [Full Text] [Related]  

  • 14. Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases.
    Alavian SM; Tabatabaei SV; Keshvari M; Behnava B; Miri SM; Elizee PK; Lankarani KB
    Liver Int; 2010 Sep; 30(8):1173-80. PubMed ID: 20629950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sustained virological response in patients with coinfection by hepatitis C virus genotypes 1 and 2, after just nine weeks of antiviral therapy: case report].
    Araújo AR; Levi JE; Almeida CM; Lima TA; Maia LP; Torres KL; Tarragô AM; Victória F; Victória M; Talhari S; Malheiro A
    Rev Soc Bras Med Trop; 2010; 43(5):605-7. PubMed ID: 21085882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.
    Pockros PJ; Nelson D; Godofsky E; Rodriguez-Torres M; Everson GT; Fried MW; Ghalib R; Harrison S; Nyberg L; Shiffman ML; Najera I; Chan A; Hill G
    Hepatology; 2008 Aug; 48(2):385-97. PubMed ID: 18570306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peginterferon plus ribavirin for hepatitis C in HIV-infected patients.
    Gholam PM
    N Engl J Med; 2004 Nov; 351(22):2340-2; author reply 2340-2. PubMed ID: 15570682
    [No Abstract]   [Full Text] [Related]  

  • 18. [Genotype 1 superresponder treat for only 24 weeks].
    MMW Fortschr Med; 2005 Dec; 147(51-52):69. PubMed ID: 16402717
    [No Abstract]   [Full Text] [Related]  

  • 19. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
    Peribañez-Gonzalez M; da Silva MH; Vilar FC; Seixas-Santos Nastri AC; Ferreira PA; Focaccia R; Mendes Correa MC
    Ann Hepatol; 2013; 12(2):228-35. PubMed ID: 23396734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A change of peginterferon may permit continuation of antiviral therapy in hepatitis C virus-infected patients with interstitial pneumonitis.
    Shimada M; Yoshida S; Kornek M; Kim SJ; Schuppan D
    Liver Int; 2010 Nov; 30(10):1552-4. PubMed ID: 20557455
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.